Fasudil hydrochloride is a new type of intracellular
Introduction
Delayed cerebral vasospasm is a serious complica tion of subarachnoid hemorrhage (SAH) which has resulted in death or severe neurological deficits in 33.5% of cases of vasospasm.12,131 Various modalities of therapy and medications have been applied to the treatment of vasospasm such as ozagrel sodi um, 14,20.27) nizofenone fumarate,16,191 dihydropyridine calcium antagonist, 1,4.10.15,17) or cisternal irrigation us ing either urokinase28) or tissue plasminogen activa tor, 5.6,22) but any satisfactory results have not yet been attained. At our institution, ozagrel sodium has been used to suppress vasospasm, since it is known to in hibit the synthesis of thromboxane A2 derived from blood platelets, so is expected to have a potent effect against vascular contraction. Ozagrel sodium allevi ates the symptoms accompanying cerebral ischemia due to vasospasm.8,14,20.27) However, we have not ob tained favorable results. The following items were compared between the two groups: neurological grading on admission (Hunt and Kosnik's classifications)), computed tomography (CT) findings on admission (Fisher's CT classification 7)), occurrence of symptomatic vasospasm during the course of treatment, occur rence of low density areas on CT during the course of treatment, functional outcome at discharge (Glas gow Outcome Scale"), and adverse effects caused by the drugs. The presence or absence of symptomat ic vasospasm was determined based on the presence or absence of focal signs and/or symptoms such as disturbed consciousness, impaired speech, or hemiparesis. Low density areas on CT scans not de tected on the day after surgery, but appearing 1 to 3 weeks later were defined as cerebral infarction caused by vasospasm. Clinical data were analyzed by the chi-square test with Yates' continuity correc tion. A p value of less than 0.05 was considered sig nificant.
Results
There were no significant differences in clinical characteristics between the two groups in age and duration of hospitalization and location of ruptured aneurysms ( Table 1 ). The severity of neurological symptoms on admission (Hunt and Kosnik) showed the incidence of grade I patients was greater in Group A than in Group B, but without significant difference. There was little difference in the inci dence of grade III patients between Groups A and B. CT findings on admission (Fisher's system) showed no significant difference between the two groups. Low density areas were detected in 19 patients in Group A and six patients in Group B. There was a statistically significant difference between Groups A and B (p < 0.01). Clinical outcome at discharge (Glasgow Outcome Scale) showed a greater incidence of good recovery and moderate disability in Group B than in Group A, but there was no statistically significant difference in summary results ( Table 2 ). The causes of poor out comes in both groups were further analyzed. Twelve of 21 patients in Group A were affected by vasospasm, four by surgery, three by primary brain damage, and two by systemic complication.
In con trast, only three of 13 patients in Group B seemed to be affected by vasospasm, four patients by surgery, four by primary brain damage, and two by severe sys temic complication.
So in the revised results, by ex cluding patients whose outcome was worsened by any cause other than vasospasm (Table 2) , the in cidence of good recovery and moderate disability in the two groups was statistically different (p < 0.01). This study was a prospective, non-contemporane ous, non-randomized clinical trial, so only the ozagrel sodium group (Group A) and combination of ozagrel sodium and fasudil hydrochloride group (Group B) were simply compared and analyzed. In Group A, low density areas on CT scans were seen in 19 (79.2%) of 24 patients who experienced sympto matic vasospasm, whereas in Group B, low density areas were observed in six (33.3%) of 18 patients who experienced symptomatic vasospasm. So there was no statistically significant difference in the oc currence of symptomatic vasospasm, however, there was statistically significant difference in the inci dence of low density areas on CT scans (p < 0.01) be tween the two groups. The ischemic symptoms re lated to vasospasm were felt to be more reversible 
Commentary
This study raises important points o f principle in the treatment of delayed vasospasm and other conditions. It was, as the authors point out, a comparison of two consecutive groups o f patients, rather than a ran domized trial. However, the latter would have been much more expensive (and probably not supported by a pharmaceutical company) and difficult to carry out, and would also have taken much longer. Further more, if one feels from the evidence of other studies that a new treatment (fasudil in this case) is effective, then it is difficult ethically to justify further trials where some patients do not receive that treatment.
In spite of this deficiency the results are encourag ing, with 42% incidence of symptomatic vasospasm in those receiving ozagrel only, and 30% in the group with fasudil as well. The difference in the frequency of CT low density areas (I always have a problem with this rather loose term -if an area o f low density, due say to transient edema, appears on a scan one week and is gone a week later, then it is meaningless. A difference in incidence of low density areas that are due to an infarct and persist unchanged would be much more relevant clinically) did reach statistical sig nificance. As noted, the effect o f the vasospasm was possibly less severe in the second group; 79% o f those with vasospasm in the first group also developed low density areas, compared with 33% in the second group.
From the patient's point of view these findings are not relevant, but the outcome is. There is a trend, which reaches statistical significance i f causes o f a poor outcome apart from vasospasm are eliminated (Table 2 of this article), towards a better outcome in the group with combined treatment (the functional outcome at discharge measured here is often not strongly related to capabilities six or 12 months later). Perhaps with more cases a significant difference would have been found between the whole groups in Table 2, but that was not possible in the context of this study.
It should be remembered that delayed vasospasm is a multi-factorial problem, with a complex cascade of biochemical events leading eventually to symptomatic ischemia. It seems eminently reasonable, therefore, to do as this group has done and attack the problem at all possible points along this chain of events. The mul ti-action calcium antagonist fasudil or AT877 may be especially well suited for such a purpose.
